CLYYF (Celyad Oncology) Moat Score: 4/10 (As of Jun. 27, 2026)


CLYYF Celyad Oncology SA CLYYF
13 GF Score
Price $0.25
GF Value $0.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Moat Score?

Celyad Oncology CLYYF 13 Moat Score is 4 as of Jun. 27, 2026. GuruFocus rates CLYYF with a GF Score™ of 13/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,404 Biotechnology companies, Celyad Oncology ranks better than 88.82% on this metric.

Celyad Oncology has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Celyad Oncology has Narrow Moat: Celyad Oncology SA has a modest moat due to its intellectual property in oncology treatments. However, it faces significant competition and lacks strong brand strength or market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Celyad Oncology might have Narrow Moat - Discernible but modest moat.

Celyad Oncology  (OTCPK:CLYYF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Celyad Oncology Moat Score Related Terms

CLYYF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Celyad Oncology's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Moat Score distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Moat Score falls into.


CLYYF
13GF Score
Celyad Oncology SA CLYYF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Celyad Oncology (CLYYF) has a Moat Score of 4 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Celyad Oncology ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Celyad Oncology's Moat Score too high?
Celyad Oncology's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Celyad Oncology's value of 4 is 100% above this industry median. Based on the distribution chart, Celyad Oncology ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celyad Oncology has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #157 out of 1404 companies for Moat Score. This places Celyad Oncology in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Celyad Oncology's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $0.25 — trading 43.2% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Moat Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of $0.25 is trading 43.2% below its estimated GF Value™ of $0.44. GuruFocus considers Celyad Oncology to be Significantly Overvalued.

Key valuation signals for CLYYF:

  • Moat Score: 4
  • GF Value™: $0.44 vs. price of $0.25 (43.2% below fair value)
  • GF Score™: 13/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1404)

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score

Get the complete analysis for CLYYF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.44
GF Value